Cancer feature: cnaPANCAN307

AC027763.2 AC129492.6 ACADVL ACAP1 ALOX12 ALOX12B ALOX15B ASGR1 ASGR2 ATP1B2 BCL6B C17orf49 C17orf61-PLSCR3 C17orf74 CD68 CHD3 CHRNB1 CLDN7 CLEC10A CNTROB CTD-2545G14.7 CTDNEP1 CYB5D1 DLG4 DNAH2 DVL2 EFNB3 EIF4A1 EIF5A ELP5 FBXO39 FGF11 FXR2 GABARAP GPS2 GUCY2D KCNAB3 KCTD11 KDM6B LSMD1 MPDU1 NEURL4 NLGN2 PHF23 POLR2A RNASEK RNASEK-C17orf49 RP11-1099M24.7 RP11-542C16.2 RP1-4G17.5 SAT2 SENP3 SHBG SLC16A11 SLC16A13 SLC2A4 SOX15 SPEM1 TEKT1 TMEM102 TMEM256 TMEM256-PLSCR3 TMEM88 TMEM95 TNFSF12 TNFSF12-TNFSF13 TNFSF13 TNK1 TP53 TRAPPC1 WRAP53 XAF1 YBX2 ZBTB4

Known Driver Genes: TP53

Copy number alternation: loss

Nutlin-3a (-)

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer